1998 Actual 1999 Actual 2000 Actual 2001F/C 2002 F/C

Total Canada EPREX$ 83,552,290 $ 99,021,852 $ 106,000,000 $ 118,601,941 $

Total Ontario EPREX$ 37,556,728 43,526,641 48,063,792 57,686,003 TBD
Territory EPREX$ 5,627,827 7,067,660 7,689,891 9,149,000
% chg vs. YAG (year ago) 200.0% 24.0% 8.8% 19.0%
SOM District 15.0% 16.2% 16.0% 15.9%
SOM National 6.7% 7.1% 7.3% 7.7%
Territory EPREX $ Hospital 5,627,827 7,067,660 7,689,891 9,149,000
% chg vs YAG (year ago) 196.0% 25.6% 8.8% 19.0%
SOM (territory number) 100.0% 100.0% 100.0% 100.0%
Territory EPREX $ Retail
% chg vs YAG (year ago)
SOM (territory number) 0.0% 0.0%
Observations:
NEPHROLOGY BUSINESS UNIT
ONTARIO PLAN 2002
- MoH data is collected for each account. As of Sept 24, 2001, total teritory sales for Eprex* in the hsp segment that is as f ollows:
Humber $7,100, CVH, Orillia, St. Joe's, Oakville = $0.00
- It is assumed that the majority of sales coming out of the hsp segment represent CRF sales.
- The territory saw a sales increase of 9% in 2000 due to patient expansion.
- IV Iron had a significant impact on Eprex* sales in all accounts affecting both the adoption rates and the average weekly dos ages
acheived in the centres. Hb levels > 110 significantly increased in all accounts.
- The sales have not been adjusted for the clinical trial use of Eprex* in the territory which has been estimated at ~ $200,000 .
- The impact of a competitor (NESP) has not been built into the sales forecast for 2001.
-
Territory is forecasting to exceed 2001 sales budget. Many programs who have had expansions pending for the last few years have finnaly seen these
expansion realize. Combined with higher Hb's and steady adoption rates, the territory should complete 2001 above expectation s awith several more
expansion projects to take place in 2002-2003 (for HD , PD and PRI).
EXPRE SALES ($) HOSPITAL
Key Account 1999 Actual 2000 Actual 2001 Forecast 2001 Actual (Oct YTD) % Change YTD
Share of
Territory 2002 F/C
1. Credit Valley Hsp 2,289,990 $ 2,653,090 $ 2,434,444 17.3%
Peel 361,689 $ 522,368 $ 765,771 89.4%
Etobicoke 47,475 $ 73,379 $ 119,114 148.0%
Orangeville 111,862 $ 96,444 $ 138,913 23.3%
Total CVH & Satellites 2,811,016 $ 3,345,281 $ 3,842,580 $ 3,458,242 32.5% 42.0%
2. Humber River Regional 1,877,769 1,924,195 2,195,760 2,195,871 41.4% 24.0%
3. Orillia 989,176 700,036 748,098 33.1%
Collingwood 69,131 106,356 107,160 33.3%
Alliston 88,407, 128,592 101,802 0.0%
Barrie 21,711 97,578 207,898 28.4%
Huntsville 40,721 79,148 82,081 41.8%
Penetang - 77,913 67,588 5.1%
Total Orillia & Satellites 1,120,739 1,189,623 1,463,840 1,314,627 37.3% 16.0%
4. St. Joesph's 661,806 552,390 914,900 797,751 61.6% 10.0%
5. Oakville Trafalgar 507,933 678,402 731,920 587,415 2.8% 8.0%
6
Total hospitals 7,067,660 $ 7,689,891 $ 9,149,000 $ 8,353,986 35.1% 100.0% TBD
Observations:
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN 2002
KEY ACCOUNTS
Territory sales (Oct ytd) demonstrates HUGE growth of 29% predicting 2001 sales performance at 108% to forecast (yes, the 2001 sales f/c was
large!) This growth is due to increases in patient numbers for HD, PD and PRI with the PRI patient segment comprising the largest patient group in
most centres. Percent of patients with Hb's >110 remained above 73-75% in all patient segments but the feeling is that this # may be higher if the data
were collected more frequently......
HD expansions took place at CVH-24, Peel-2, Barrie-6, Collingwood-2 and Oakville-8. The PD segment finally experienced some growth in all
programs - it has been on a decline for years. There is a significant increase in the use of Eprex* in PRI patients.

-Territory growth expected this year as several HD expansions will occur.
- High use of IV Iron in all sites dramatically reduced Average weekly Eprex dosages and some adoption rates but increased percent of patients in the target
Hb range (110-120)
- 2002 f/c yet to be approved.
- 2001 f/c has not been adjusted to reflect patients in JOI clinical trials who receive Eprex* for free (~$200,000) and for the pending introduction of a
competitor.
- using indication specific sales data from TSA which is not always similar to the MoH data ollected by account
EPREX SALES ($)
RETAIL
Key Account 1999 Actual 2000 LE 2001 BP
Share of
Territory 2000
% Change vs
YAG Latest Forecast Latest Actuals % vs Forecast
1. #DIV/0! #DIV/0! #DIV/0!
2. #DIV/0! #DIV/0! #DIV/0!
3. #DIV/0! #DIV/0! #DIV/0!
4. #DIV/0! #DIV/0! #DIV/0!
5. #DIV/0! #DIV/0! #DIV/0!
6 #DIV/0! #DIV/0! #DIV/0!
Total retail - $ - $ - $ #DIV/0! #DIV/0! - $ - $ #DIV/0!
Observations:
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN
KEY ACCOUNTS
It is assumed that there are no sales for renal captured in the retail sector.
Similarly, the colletion of MoH data for each account has confirmed thatapproximately $87,000 of Erpex* sales from the hospit al segment can be attributed to
surgery and oncology sales.
-
-
-
-
-
-
Total
# # % # % # % # % # % # %
1999
1,409 768 55% 194 14% 447 32% 707 92% 178 92% 272 61%
2000
1,981 911 46% 199 10% 871 44% 830 91% 178 89% 410 47%
2001
2,550 1,031 40% 218 9% 1,301 51% 974 95% 215 99% 605 47%
2002
Observations:
Pre-Dialysis
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN 2002
Key Account Summary (Total Territory)
Pre-Dialysis Hemo PD
Patient Statistics / Adoption Rates

Hemo PD
CRF PATIENTS EPREX ADOPTION
-Extensive use of IV iron has allowed more patients to achieve t-Hb's without Eprex* AND has resulted in more
patients having their Eprex* held when Hb's rise quickly following a course of IV iron.
- Patients whose Hb is in the t-Hb range of 110-120 will experience rapid Hb rises if IV iron therapy is given
when the t-ferritin of 250 - 500 ng/ml is set as goal.
- Many units now strive for a t-ferritin between 250-500 ng/ml which has served to reduce Eprex* weekly
dosages and adoption rates.
-PRI patients captured here do include ERI patients (pts with CrLl < 250 umol/L who do not yet qualify for MoH
funded Eprex therapy.

YTD there has been a 29% increase in total CKD patients:13% growth in HD, 9.5% in PD and 49% in the PRI population. The PRI patient
group now represents 51% of all CKD patients. HD Expansions have ocurred to date: CVH-24 HD, Peel - 2 HD, Barrie - 6 HD,
Collingwood - 2 HD, Oakville - 8 HD stations. There are more patients being seen who have CrCl's < 250 (Nephropathy Clinics) but
these patients are not yet candidates for Eprex* therapy. Eprex* AR's increased for HD and PD but remained the same for PRI -
presumably due to early identification of patients, many of which who are not yet anemic. Similarly, the PRI patient # includes the ERI
patient group whi have CrCl < 250 and are not yet eligible for Eprex* therapy.
Total
# # % # % # % # % # % # %
1999
622 311 50% 95 15% 216 35% 304 98% 87 92% 173 80%
2000
780 338 43% 107 14% 335 43% 321 95% 98 92% 177 53%
2001
936 407 44% 122 13% 407 43% 426 95% 122 100% 282 69%
2002
Observations:
Patient Statistics / Adoption Rates
Hemo PD
CRF PATIENTS EPREX ADOPTION
Pre-Dialysis
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN 2002
Key Account Summary - CREDIT VALLEY HOSPITAL & Satellites
Pre-Dialysis Hemo PD
- HD: CVH=248, Watline=36, Peel=100, Headwaters=23, (Sussex=40). PRI: CVH=230, Peel = 89, Etobicoke = 88
- Predialysis includes Predialysis and Transplant patients at CVH, Peel & Etobicoke
- ERI patients do not yet qualify for funded Eprex* therapy as CrCl < 250 mmol/L
- PD and Predialysis patients exist only at CVH site - none at the satellites
- Satellites include Watline, Orangeville, Peel and Etobicoke Hospitals (Sussex included in the above #'s).
- Dr. Wu and Wadgymar are invloved in 2 clinical trials with 25 pts expected to be enrolled by year end 2001. -
CVH has finally realized it's long awaited expansion to the "Watline site" effective September 1/01.
HD, PD and PRI growth YTD is 20% (without Sussex), 14% and 22% (ERI & PRI pts).
Eprex* adoption rates have remained the same in HD and increased in PD and PRI.
Satellites = Watline, Orangeville, WOHC-Brampton & Etobicoke Sites, Sussex Centre (not previously included)
Total
# # % # % # % # % # % # %
1999
346 162 47% 46 13% 138 40% 139 86% 42 91% 55 40%
2000
503 203 40% 43 9% 257 51% 177 87% 41 95% 114 44%
2001
565 233 41% 43 8% 289 51% 206 88% 41 95% 150 52%
2002
Observations:
Pre-Dialysis
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN 2002
Key Account Summary - Humber River Regional Hospital
Pre-Dialysis Hemo PD
Patient Statistics / Adoption Rates
Hemo PD
CRF PATIENTS EPREX ADOPTION
- Predialysis includes Predialysis and Transplant patients
- ERI patients do not yet qualify for funded Eprex* therapy as CrCl < 250 mmol/L
The HD, PD and PRI groups have grown 15%, 0% and 13% to date with the PRI population accounting
for 51% of all CKD patients. While patient stats (lab values) are dated (spring '01), 2 OCC's are now in
place and will drive routine patient assessments on a regular basis. The HD adoption rate grew to 88%
but understand that the nocturnal patients are included in this calculation and Eprex* AR in this patient
group is only 70%. PD AR remained the same and PRI increased to 52%.

- Predialysis includes Predialysis and Transplant patients
- ERI patients do not yet qualify for funded Eprex* therapy as CrCl < 250 mmol/L
- potential HD expansion 2002-2003 - Keele Street site.
- very strong OCC representation at this site.
- KOL - David Mendelssohn at this site.

-
Total
# # % # % # % # % # % # %
1999
242 166 69% 15 6% 61 25% 140 84% 13 87% 27 44%
2000
258 166 64% 9 3% 83 32% 158 95% 7 78% 33 40%
2001
272 171 63% 19 7% 82 30% 169 99% 18 95% 58 71%
2001
Observations:
Pre-Dialysis
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN 2002
Key Account Summary (Orillia and Satellites)
Pre-Dialysis Hemo PD
Patient Statistics / Adoption Rates
Hemo PD
CRF PATIENTS EPREX ADOPTION
- Predialysis includes Predialysis and Transplant patients
- ERI patients do not yet qualify for funded Eprex* therapy as CrCl < 250 mmol/L
- PD and Predialysis patients exist only at Orillia site - none at the satellite units.
- There are no planned clinical trials expected for Orillia in 2001.

Orillia has 5 satellites: Collingwood, Huntsville, Penetaguishine, Alliston and Barrie. There has been
a small growth in the HD segment, primarily due to expansions in Barrie and Collingwood. The PD
program increased significantly and the PRI program remained static. the PRI program is currently
working through Momentum to devlop the infastructure tand services to support more PRI patient
access. Adoption rates for all modalities increased in 2001 with string support from the OCC.
Total
# # % # % # % # % # % # %
1999
108 58 54% 38 35% 12 11% 58 100% 36 95% 3 25%
2000
151 63 42% 33 22% 55 36% 63 100% 32 97% 18 33%
2001
193 75 39% 43 23% 75 38% 74 99% 41 95% 39 52%
2002
Observations:
Patient Statistics / Adoption Rates
Hemo PD
CRF PATIENTS EPREX ADOPTION
Pre-Dialysis
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN 2002
Key Account Summary -St. Joseph's Health Centre
Pre-Dialysis Hemo PD
- Predialysis includes Predialysis and Transplant patients
- ERI patients do not yet qualify for funded Eprex* therapy as CrCl < 250 mmol/L
- There are no clinical trials taking place at this centre now.
- HD expansions are scheduled for Q2-3, 2002 (20 HD stations, offsite).
- There was no PRI co-ordinator, Nurse Manager or Clinical Coordinator for 5 months in
2001.
St. J oe's has seen an increase in patient #for each modality (HD -+19%, PD - +30%, PRI - +36%) as
previous staffing issues have finally been addressed.), Eprex* adoption rates have stayed the same
(HD, PD) and icnreased in the PRI pt segment. The unit will plan an off-site HD expansion for the
summer of 2002. The team is currently looking for another Nephrologist .
Total
# # % # % # % # % # % # %
1999
91 71 78% - 0% 20 22% 66 93% - 14 70%
2000
122 81 66% - 0% 41 34% 64 79% - 16 39%
2001
240 100 42% - 0% 140 58% 99 99% - 0% 76 54%
2002
Observations:
Patient Statistics / Adoption Rates
Hemo PD
CRF PATIENTS EPREX ADOPTION
Pre-Dialysis
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN 2002
Key Account Summary- Oakville Trafalgar Memorial Hospital
Pre-Dialysis Hemo PD
- Predialysis includes Predialysis, ERI and Transplant patients
- ERI patients do not yet qualify for funded Eprex* therapy as CrCl < 250 mmol/L
- There is currently NO PD program at Oakville.
- There is currently NO clinical trials taking place at this centre. Centre may enroll in the LVH study
(Dr. Pandeya) in 2001.
- 8 station HD expansion opened September '01.
Oakville Trafalgar has experienced growth in their HD and PRI programs in 2001 (HD - +23%, PRI - 241%).
They have opended another HD room with 8 stations and have expanded their ERI/PRI program to 3 full
days / week. Future emphasis will be on expansing the PRI program and to consider a PD program in
2002-2003.
Total
# # % # % # % # % # % # %
1999
- #DIV/0! #DIV/0! ##### ##### #DIV/0! #####
2000
- #DIV/0! #DIV/0! ##### ##### #DIV/0! #####
2001
- #DIV/0! #DIV/0! ##### ##### #DIV/0! #####
Observations:
Pre-Dialysis
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN
Key Account Summary (Account 6)
Pre-Dialysis Hemo PD
Patient Statistics / Adoption Rates
Hemo PD
CRF PATIENTS EPREX ADOPTION
-
-
-
-
-
-
Insert commentary here, for more space increase height of row 7.
99 00 2001 99 00 2001 99 00 2001 Frequency* Route
Hemo. 8639 9000 8747 115 110-120 110-125 116 118 115 1-3 x week SC
CVH P.D. 6448 6423 6423 115 110-120 110-125 117 120 120 1-3 x week SC
Predial. 11692 4424 6532 115 110-120 110-130 118 120 119 1-3 x week SC
Hemo. 12201 9400 9952 115 110-120 111-130 120 126 120 1-3 x week SC
HRRH P.D. 8048 7725 8702 115 110-120 111-130 120 120 121 1-3 x week SC
Predial. 9873 5500 6012 115 110-120 111-130 121 125 121 1-3 x week SC
Hemo. 9634 9300 9649 115 110-120 110-120 114 118 117 1-3 x week SC
OSMH P.D. 11500 5071 6431 115 110-120 110-120 123 118 123 1-3 x week SC
Predial. 5370 4000 5509 115 110-120 110-120 114 115 111 1-3 x week SC
Hemo. 7827 9492 9649 115 110-120 110-120 112 110 115 1-3 x week SC
SJHC P.D. 6778 5000 6857 115 110-120 115-125 110 106 115 1-3 x week SC
Predial. 6666 4222 5526 115 110-120 110+ 109 103 113 1-3 x week SC
Hemo. 10424 8600 7964 115 110-120 110-120 118 120 115 1-3 x week SC
OTMH P.D. n.a. 115 110-120 n.a. n.a. n.a. n.a. 1-3 x week SC
Predial. 6714 4000 4744 115 110-120 110+ 118 118 114 1-3 x week SC
Observations:
Centre
Average Total Weekly dose Target Hgb Actual Hgb Dosing Regimen
DOSAGE OF EPREX and HB LEVEL
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN 2002
- Average Hb's remained in the target range in 2001.
- note that the ability of the data to truely reflect the % of patients in the t-Hb range is limited as stats collections are completed in some centres
monthly (greater degree of accuracy), but in most 2-3 times per year.
- Average Hb's by modailty may change up or down a few points but the key is that the averages remain in the 110-120 range and that more patients
are seeing Hb's > 120.


The average weekly dose of Eprex* in HD patients decreased in 2 accounts and increased slightly in 3 - impact of IV Iron in HD
programs is key with a note that IV iron is not used as frequently in satellite centres. The dosages for PD patients stayed the same or
increased in all centres. The most notable change is that the Eprex* dosages for PRI patients did increase in all programs as a result of
ramping Hb's higher and starting patients sooner on Eprex* therapy. Please note the limitations of analyzing averages when data may
only be collected 2-3 times per year.
Hemo. 75%
CVH P.D. 26%
Predial. 29%
Hemo. 24%
HRRH P.D. 23%
Predial. 15%
Hemo. 54%
Orillia P.D.
Predial.
Hemo. 0%
St. Joe's P.D. 0%
Predial.
Hemo. 53%
Oakville P.D.
Predial.
Observations:
33%
73%
100%
67%
90%
70%
98%
0%
85%
60% 39%
0%
61%
28%
Centre P.O. I.V.
3%
60%
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN 2002
Iron Management Chart (Percentage)
12%
90%
85%
34% 25%
18%
Oral & IV Intermittent
3%
30%
3%
3%
43%
- increasing use of IV Iron in ALL modalities
- cost still an issue but the higher Hb benefit seems to justify the cost so less concern.
-
-
-
-
Increasing use of IV Iron and Ferritin thresholds persisted in 2001.While cost of IV iro, whether in conbination with an oral iron preparation
or on it's own, centres arecomplaining less of the IV Iron cost and noticing more the higher Hb's that can be acheived with l ower doseages
of Eprex*. In maintaining these high ferritins, there is the frequent scenario of patients having very high Hb' peaks followi ng a course of IV
Iron to maintitain high ferritin levels(> 200-300). This has shed some concern about the future potential for clotting incidents.
Hemoglobin chart: (Percent of patients)
Centre Modality
99 00 2001 99 00 2001 99 00 2001 99 00 2001
Credit Valley Hemo. 16% 15% 12% 21% 10% 18% 30% 36% 31% 33% 39% 39%
& Satellites P.D. 12% 9% 9% 12% 12% 16% 34% 28% 37% 42% 51% 38%
PRI 10% 15% 34% 41%
Humber Hemo. 8% 9% 9% 8% 7% 18% 44% 44% 27% 40% 40% 46%
P.D. 5% 7% 5% 20% 12% 10% 35% 26% 30% 40% 55% 55%
PRI 5% 12% 33% 50%
Orillia
Hemo.
13% 10% 10% 24% 15% 15% 29% 43% 36% 34% 32% 39%
P.D.
7% 7% 15% 13% 10% 15% 47% 44% 28% 33% 39% 39%
& Satellites PRI 15% 32% 23% 30%
St. Joe's Hemo. 24% 16% 17% 14% 19% 16% 34% 42% 28% 28% 23% 39%
P.D. 26% 31% 12% 26% 20% 27% 22% 23% 24% 26% 26% 3700%
PRI 25% 22% 36% 22% 28% 22% 11% 34%
Oakville Hemo. 11% 8% 14% 20% 14% 15% 25% 30% 39% 44% 48% 32%
PRI 0% 0 11% 0% 0 17% 0% 0 22% 0% 0 50%
% TOTAL HEMO 16% 12 11% 21% 16 16% 28% 39 32% 35% 34 41%
% TOTAL P.D. 14% 12 9% 16% 13 16% 32% 27 32% 37% 47 43%
% TOTAL PRI 10% 15% 31% 44%
Observations:
110 < Hbg < 120 Hbg > 120
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN 2002
Hbg <100 100 < Hbg < 110
- The percent of patients with Hb's > 110 has remained > 73% for HD and > 75% for PD & PRI.
- Note - data sets refelct a snapshot in time - the less frequently the data is collected, the less accurate the data.
- Most data sets are collected 3-4 times per year, some 1x/year, two accounts, bi-monthly.
-
The cardiomyopthay message continues to have a positive impact on the percent of patients who are in or above the 110-120 g/L Hb range. Similar to last year, the
% of patients with Hb's > 110 are: HD: 73%, PD & PRI- 75%. While we would expect more patients in the t-Hb range (>110) versus 2000, this is not surprisingly
demonstrated in the data. First, centres feel that > 80-85% of patients do have t-Hb > 110 most of the time. However, data management systems do not yet exist
that would allow accurate tracking of patient data on a bi-weekly or monthly basis. Secondly, centres do know that they are frequently asked to reduce or hold
Eprex* doses when Hb's exceed 125-135 - usually due to a course of IV iron that shoots the Hb up necessitating a fast change in Eprex dose which is quickly
followed by a plunging Hb. In fact, the OCC's have identified that this oscillating Hb level in patients is becoming very common and of high concern in those
patients with cardiac and clotting risks. In summary, Hb's have remained within the target range for 2001 but there is a need to identify a data management
system that will allow accurate pt assessments on a regular basis. The CSN guideline of 110-120 g/L and the cardiomyopathy message are working welll to raise
the committment of Nephrologists to maintain improved anemia status is all renal patients. The OCC's are also continuing to drive this approach effectively.
Program Assessment
Objectives Costs
Impact on
Business/Incremental
Sales
Assessment
1 PRI Workshop
Expand ERI/PRI base and
Eprex* use
Covered previously by
Marketing
More pts receive Eprex*
therapy. Are identifying
more ERI pts which is our
future Eprex* PRI base.
Anti-competitive as
building relations with key
customers
Continue in 2002
2 Momentum
To have all programs
operating a stage 3-4
program in 2-3 years
Shared by centre and
marketing
The more PRI clinic
settings we can establish,
the more patients that can
be seen, managed and
available for Eprex*
therapy. Cardiomyopathy
message will be key in
2001 for this patient group.
Continue in 2002
3 OCC
To have an OCC in place
in each centre. To imrpove
the anemia status of all
patients followed by the
OCC. To have a database
program to assist the OCC
in this monitoring
endeavour.
Shared by centre and
marketing
The OCC position will
afford our timely access to
data which will allow us to
effectively facilitate patient
management strategies
(CV risk factors) and to
monitor our impact in the
marketplace.
Continue in 2002
4 Contractual Agreements
To have all accounts
registered in a contract by
the end of Q2 2001. To
use the funds to develop
value-added initiatives that
will support Eprex* therapy
and proetct the business in
the event a competitor
enters the market.
Head Office
To provide an anti-
competitive barrier to our
business. To wrap
significant value-added
programs around Eprex* to
eliminate the desire for
customers to switch
significant market share to
the competitor.
Continue in 2002
5 Cardiomyopathy Message
To raise Hb's in all patient
groups with key emphasis
on the ERI / PRI patient
poopulation.
shared by territory and
marketing
To raise Hb levels in all
modalities which will
require increased Eprex*
use - note that IV Iron use
may blunt this response.
Continue in 2002
6
7
Observations:
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN 2002
Program
J OI continues to be recognized for facilitating programs that affect improvements in renal management policies, processes
and health status of patiients, of which anemia management is only one facet. Continuing these initiatives should
strengthen customer commitment to Eprex* and the programs ilinked to J OI - this trust and patient focussed strategy will
represent the greatest anti-competitive barrier we could implement.
-
-
-
-
-
-
Relationships (describe only for KEY customers)
Title Status of Relationship
1
2
3
4
5
6
Title Status of Relationship
1
2
3
Key Contacts
Key Decision Makers
NEPHROLOGY BUSINESS UNIT
ONTARIO PLAN
Centre Name:
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Insert commentary here, for more space increase height of row 7.
Relationships (describe only for KEY customers)
Title Status of Relationship
1
2
3
4
5
6
Title Status of Relationship
1
2
3
Key Contacts
Key Decision Makers
NEPHROLOGY BUSINESS UNIT
ONTARIO PLAN
Centre Name:
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Insert commentary here, for more space increase height of row 7.
Relationships (describe only for KEY customers)
Title Status of Relationship
1
2
3
4
5
6
Title Status of Relationship
1
2
3
Key Contacts
Key Decision Makers
NEPHROLOGY BUSINESS UNIT
ONTARIO PLAN
Centre Name:
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Insert commentary here, for more space increase height of row 7.
Relationships (describe only for KEY customers)
Title Status of Relationship
1
2
3
4
5
6
Title Status of Relationship
1
2
3
Key Contacts
Key Decision Makers
NEPHROLOGY BUSINESS UNIT
ONTARIO PLAN
Centre Name:
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Insert commentary here, for more space increase height of row 7.
Relationships (describe only for KEY customers)
Title Status of Relationship
1
2
3
4
5
6
Title Status of Relationship
1
2
3
Key Contacts
Key Decision Makers
NEPHROLOGY BUSINESS UNIT
ONTARIO PLAN
Centre Name:
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Insert commentary here, for more space increase height of row 7.
Relationships (describe only for KEY customers)
Title Status of Relationship
1
2
3
4
5
6
Title Status of Relationship
1
2
3
Key Contacts
Key Decision Makers
NEPHROLOGY BUSINESS UNIT
ONTARIO PLAN
Centre Name:
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Insert commentary here, for more space increase height of row 7.
Hospital / Customer Nature of Activity
CVH - Dr. Wu, Wadgymar,
Humber (Berall, Hercz)
NESP Trial, in HD and PRI patients. At Humber, they are also participating in the Ca PO4 product trial.
CVH - Dr. Wu
Venofer/Ferrlicit
Increased use of IV Iron represents a serious impact on Eprex* consumption as per weekly average dosages and adoption rates.
Amgen
HMR (RPR)
Other
Company
NEPHROLOGY BUSINESS UNIT
TERRITORY PLAN
COMPETITIVE INTELLIGENCE
Roche
positive/negative
NESP trials continue at Credit Valley and Humber well into 2001. IIV Iron use is on the rise. Should an IV Iron preparation receive NOC in 2001, IV Iron use will increase and this will
continue to have a negative impact on Eprex* weekly dosages and adoption rates, Most centres are now pursuing ferritin level s of 250-500 ng/ml versus the 100 ng/ml outlined in our
product monograph, It is interesting to note that centres have absorbed the cost of IV Iron without complaint but know that it will be a money maker once a DIN # is attained as billing
can then be applied to ODB, including a prescription upcharge fee.